Bristol-Myers Squibb Australia Pty Ltd

Opdivo (nivolumab), in combination with platinum-doublet chemotherapy, was approved for the neoadjuvant treatment of patients with resectable non-small cell lung cancer.

Opdualag (Nivolumab and Relatlimab) has been approved for the treatment of patients with unresectable or metastatic melanoma who are at least 12 years old.

AusPAR for Sotyktu (deucravacitinib) for treatment of adult patients with moderate-to-severe plaque psoriasis.

AusPAR for Camzyos (mavacamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy.

AusPAR for Opdivo (nivolumab) for the treatment of adjuvant treatment of patients with muscle invasive urothelial carcinoma (MIUC).

Australian Public Assessment Report for Nivolumab and ipilimumab

Australian Public Assessment Report for Nivolumab

Australian Public Assessment Report for Nivolumab

Australian Public Assessment for Dasatinib

Australian Public Assessment Report for Abatacept